Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

Growth hormone treatment stimulates growth in short children with chronic renal failure.

Who Took Part

According to the abstract, 38 children were involved.

PubMed indexes the participants as young children, children and teenagers, both men and women.

The researchers followed 38 initially prepubertal children with chronic renal failure treated with growth hormone for a mean of 5.3 years until they reached their final adult height.

The mean (+/-SD) age at the start of treatment was 10.4+/-2.2 years, the mean bone age was 7.1+/-2.3 years, and the mean height was 3.1+/-1.2 SD below normal.

How the Study Was Run

Fifty matched children with chronic renal failure who were not treated with growth hormone served as controls.

What Was Measured

PubMed files the paper under topics including Body Height, Bone Development, Growth, Growth Disorders, Human Growth Hormone, Kidney Failure, Chronic and Puberty.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 38 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (The New England journal of medicine), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.